

## ABSTRACT TOPIC LIST (revised Dec 2018)

### A: Preclinical and translational aspects, including radiopharmacy, radiochemistry and drug development

#### **A1 Preclinical and translational aspects**

##### A11 Preclinical aspects

- A111 Animal models and in-vitro studies
- A112 Tumor biology
- A113 Biology, benign disease

##### A12 Translational aspects

- A121 Cardiology
- A122 Neurology
- A123 Oncology
- A124 Therapy

#### **A2 Radiopharmacy, radiochemistry, drug development**

##### A21 Drug development

- A211 Radiopharmacokinetics and drug development
- A212 New biological targets and ligands

##### A22 Radiopharmacy

- A221 Radiopharmaceuticals - SPECT
- A222 Radiopharmaceuticals - PET
- A223 Radiopharmaceuticals – Therapy
- A224 Radiopharmaceuticals – Multimodal / optical probes
- A225 Quality Control & Quality Assurance

##### A23 Radiochemistry

- A231 Radionuclide Production
- A232 Radiopharmaceutical Preparation

#### **B: Technical aspects**

#### **B3 Instrumentation and data analysis**

##### B31 Instrumentation

- B311 General aspects
- B312 Metric and intervention
- B313 SPECT and SPECT/CT
- B314 PET and PET/CT
- B315 PET/MR
- B316 Optical imaging
- B317 Imaging guided surgery

##### B32 Data analysis

- B321 Data analysis and management
- B322 Image reconstruction
- B323 Artificial analysis and Radiomics
- B324 Quality control, performance and standardization
- B325 Neurology: data analysis and quantification
- B326 Cardiology: data analysis and imaging systems

#### **B4 Radiation protection and dosimetry**

##### B41 Radiation protection

- B411 Radiation Exposure & Protection

##### B42 Dosimetry and radiobiology

- B421 Preclinical studies
  - B4211 Preclinical dosimetry
  - B4212 Preclinical radiobiology
- B422 Clinical studies
  - B4221 Clinical dosimetry
  - B4222 Clinical radiobiology

#### **C: Clinical**

#### **C5 Diagnostic study**

##### C51 Adult study

###### C511 Oncology study

###### C511-1 General oncology

- C511-1a Radioguided surgery
- C511-1b External beam radiation therapy planning
- C511-1c Therapy response assessment

###### C511-2 Organ-based oncology

- C511-2a Brain, malignant
- C511-2b Head and neck, malignant
- C511-2c Breast, malignant
- C511-2d Lung, malignant
- C511-2e Liver, Upper GI and Pancreatic (non-endocrine), malignant
- C511-2f Colorectal, malignant
- C511-2g Prostate, malignant
- C511-2h Other urological, malignant
- C511-2i Gynaecological, malignant
- C511-2j Hemato-oncology, malignant
- C511-2k Bone and soft tissues primary and metastatic cancers
- C511-2l Melanoma, malignant
- C511-2m Endocrine, malignant
- C511-2n Thyroid, malignant
- C511-2o Other malignant, including primary of unknown origin

###### C512 Non-oncology study

###### C512-1 Cardiovascular

- C512-1a Perfusion, metabolism and receptors
- C512-1b Plaque and vascular imaging
- C512-1c Lymphatic imaging (non-oncology)

###### C512-2 Neurology

- C512-2a Neurodegeneration and dementia
- C512-2b Psychiatry
- C512-2c Neurotransmission
- C512-2d Movement disorders
- C512-2e Other Neurology (i.e.: neuroinflammation, epilepsy, headache)

###### C512-3 Endocrinology

- C512-3a Endocrinology, benign
- C512-3b Thyroid, benign

###### C512-4 Musculoskeletal, infection and inflammation

- C512-4a Orthopedics, benign, no infection
- C512-4b Bone inflammation and infection
- C512-4c Soft tissue inflammation and infection (including cardiac, lung, brain, etc.)

###### C512-5 Other clinical studies

- C512-5a Pulmonology, benign
- C512-5b Gastroenterology, benign
- C512-5c Uro-nephrology, benign
- C512-5d Hematology, benign

##### C52 Paediatric study

- C521 Oncology
- C522 Benign

#### **C6 Therapy study**

##### C61 Adult study

###### C611 Thyroid treatment

- C6111 Thyroid treatments, benign
- C6112 Thyroid treatments, malignant

###### C612 Other treatments

- C6121 NET treatments, including mIBG and peptides therapy
- C6122 Radioimmunotherapy
- C6123 Bone metastases, pain palliation
- C6124 Prostate cancer specific treatments
- C6125 Local radionuclide treatments
- C6126 Other treatments

##### C62 Paediatric study

- C621 Oncology
- C622 Benign